PARP (poly (ADP)-ribose polymerase) Inhibitors – Application of Synthetic Lethality Concepts in Cancer Treatments


Authors : Michael Halim

Volume/Issue : Volume 6 - 2021, Issue 2 - February

Google Scholar : http://bitly.ws/9nMw

Scribd : https://bit.ly/3uYM2lU

The different types and the overwhelming number of cancer cases across the globe have prompted scholars to pursue more effective therapies than traditional treatments. One approach that has demonstrated considerable progress is related to the use of PARP inhibitors. Essentially, PARP inhibitors such as Talazoparib, Olaparib and Rucaparib use a concept of synthetic lethality to kill tumour cells. According to Sebastian (2011) synthetic lethality occurs when a deficiency in one gene expression does not cause cell death while a collection of two or more deficiencies in gene expression leads to cell death. PARP inhibitors exploit this concept to eradicate tumour cells

Keywords : PARP Inhibitors, Talazoparib, Olaparib, Rucaparib

CALL FOR PAPERS


Paper Submission Last Date
31 - March - 2024

Paper Review Notification
In 1-2 Days

Paper Publishing
In 2-3 Days

Video Explanation for Published paper

Never miss an update from Papermashup

Get notified about the latest tutorials and downloads.

Subscribe by Email

Get alerts directly into your inbox after each post and stay updated.
Subscribe
OR

Subscribe by RSS

Add our RSS to your feedreader to get regular updates from us.
Subscribe